SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 --------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 14, 1997 REGENERON PHARMACEUTICALS, INC. - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) NEW YORK 0-19034 No. 13-3444607 - -------------------------------------------------------------------------------- (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY 10591-6707 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (914) 347-7000 NOT APPLICABLE - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) Page 1 of 9 INFORMATION TO BE INCLUDED IN REPORT Item 5. Other Events. On January 10, 1997 and January 14, 1997, the Company issued press releases, copies of which are included as exhibits to this filing. Item 7. Financial Statements and Exhibits. (c) Exhibits 99(a) Press Release dated January 10, 1997. 99(b) Press Release dated January 14, 1997. -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Regeneron Pharmaceuticals, Inc. By: /s/ Murray A. Goldberg -------------------------- Murray A. Goldberg Vice President, Finance & Administration, Chief Financial Officer, and Treasurer Date: January 14, 1997 -3-